

December 16, 2024

BSE Limited	Code: 532321	National Stock Exchange of India Limited
1 st Floor, P J Towers,		Code: Zyduslife
Dalal Street,		Exchange Plaza, 5 th Floor, Plot No. C/1,
Mumbai-400001		G Block, Bandra-Kurla Complex, Bandra
		(East), Mumbai-400051

Re.: Disinvestment of equity stake of Mylab Discovery Solutions Private Limited

Ref.: 1. <u>Disclosure under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations") read with SEBI Circular dated July 13, 2023 ("the SEBI Circular")</u>

2. Our earlier disclosures made on June 23, 2023, August 22, 2023, and September 18, 2023

Dear Sir / Madam,

Vide our above referred disclosures, the Company had informed that Zydus Animal Health and Investments Limited, a wholly owned subsidiary ("ZAHL") had acquired 65,06,500 equity shares of Re. 1/- (Rupee One only) each fully paid-up, representing 6.5% of the total paid-up share capital ("the Sale Shares") of Mylab Discovery Solutions Private Limited ("Mylab") from Rising Sun Holding Private Limited ("RHSPL") at an agreed consideration of Rs. 106 Crores (Rupees One Hundred and Six Crore only) vide a Share Purchase Agreement ("SPA") executed by ZAHL, RHSPL and Mylab on June 23, 2023.

Now, pursuant to the terms and conditions of the SPA, ZAHL has exercised its Put Option right to sell the Sale Shares back to RHSPL and RHSPL has agreed to acquire the Sale Shares at the original consideration amount i.e. Rs. 106 Crores (Rupees One Hundred and Six Crore only).

The Board of Directors of ZAHL at their meeting held today i.e. December 16, 2024, approved the disinvestment of Sale Shares, as per the terms and conditions of the SPA. Post that, ZAHL, RSHPL and Mylab have executed the termination deed.

The Board meeting of ZAHL commenced at 10:15 a.m. and concluded at 10:45 a.m.

Requisite disclosure as required under the SEBI Circular dated September 9, 2015 is enclosed as **Annexure-"A"**.





Please take the above information on record.

Yours faithfully, For, **Zydus Lifesciences Limited**

Dhaval N. Soni Company Secretary Membership No. FCS7063

Encl.: As above



Annexure-"A"

Sr. No.	Particulars	Responses
a)	the amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	Not applicable
b)	date on which the agreement for sale has been entered into	ZAHL, RHSPL and Mylab have executed the termination deed on December 16, 2024, for disinvestment of Sale Shares.
c)	the expected date of completion of sale/disposal	Within 15 working days from the date of signing of the termination deed.
d)	consideration received from such sale/disposal	Rs. 106 crores (Rupees One Hundred Six Crores only)
e)	brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	Rising Sun Holdings Private Limited is the buyer of the Sale Shares. The buyer does not belong to the promoter / promoter group / group companies.
f)	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	The said transaction of disinvestment of Sale Shares does not fall within related party transactions.
g)	whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	While the disinvestment of Sale Shares is outside Scheme of Arrangement, the details under regulation 37A of the Listing Regulations are not applicable, as the disinvestment is pertaining to shares and not pertaining to any undertaking.



Sr. No.	Particulars	Responses
h)	additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale	